German isotope technology provider Eckert & Ziegler has opened a new Actinium-225 (Ac-225) production facility in Rez, Czech Republic.

Developed in collaboration with the Nuclear Physics Institute of the Czech Academy of Sciences (UJF), a public institution that conducts nuclear physics research, the new lab will produce actinium isotope using “cutting-edge technologies, including a customized production line provided by Isotope Technologies Dresden”, according to Eckert & Ziegler.

Ac-225 is used for the targeted therapy of small tumours and metastases, with demand for it expected to increase over the next decade. Commercial production at Rez is scheduled to begin at the beginning of Q3 2024 after additional testing.

Dr. Lutz Helmke, managing director of Eckert & Ziegler Radiopharma, said: “Eckert & Ziegler, in conjunction with UJF, has explored one of the most promising cyclotron-based production pathways for Ac-225. Our collaboration signifies a major leap forward in isotope production, addressing the critical shortage of this isotope poised to revolutionize modern oncology.”

Prof. Ondřej Lebeda, head of radiopharmaceuticals at UJF, added: “Today’s opening marks a significant achievement in our collaboration with Eckert & Ziegler. This new facility is a testament to our joint dedication to innovation in the therapeutic landscape for many cancer patients.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.